Dr. John Cush RheumNow
4 years 9 months ago
RESTORE trial: yet another failure for PRP injections for knee #OA. Study of 288 Knee oA over 50 years - knee pain scores of −2.1 vs −1.8 on an 11-point scale (range, 0-10) and no difference between PRP and PBO at 12 moshttps://bit.ly/3dZ5ebW
The U.S. Centers for Disease Control and Prevention (CDC) yesterday recommended Americans has recommended the two authorised mRNA COVID-19 vaccines over Johnson & Johnson's adenovirus COVID-19 vaccine, primarily due to the rare reports of thrombosis with thrombocytopenia syndrome (TTS).
The CDC Advisory Committee on Immunization Practices (ACIP) met to consider recent safety data regarding the J&J vaccine.
Dr. John Cush RheumNow
4 years 9 months ago
SOBI has received a positive opinion by the EMA's CHMP on Kineret (anakinra) for the treatment of COVID-19 in adult patients with pneumonia requiring supplemental oxygen or at risk for progressing to severe respiratory failure. Final approval pending https://t.co/1bJYae38hw
Rheumatologists are well aware that inflammation and immune dysregulation are prime contributors to cancer risk, but do oncologists carry the same impressions? A large study from JAMA Oncology shows that patients with immune-mediated diseases (IMD) have an overall increased risk of cancer, especially in organ-specific immune-mediated diseases.
Donna Hoyne donna_hoyne
4 years 9 months ago
It has been a absolute honor to serve the rheum community. Your generous friendship and the ideas sparked on this account inspired me. It was a difficult decision, but yesterday was my last official day at @ACRheum. Thank you for 20+ years of pure goodness. https://t.co/sjAQcgQcSh
Dr. John Cush RheumNow
4 years 9 months ago
NRMP has released match results for adult Rheumatology programs. From a total of 125 programs, 120 filled & 98% of Rheum slots (266/272) filled. Rheum was one of few to fill >95% slots (also Allergy, cardiology, Endo, GI, Hem/Onc, Pulm/Critical Care https://t.co/7ASNKwB4ZS https://t.co/7fDrqG2WRM
Dr. John Cush RheumNow
4 years 9 months ago
NRMP announced match results for Pediatrics & Specialties. Unfortunately 31% of positions are unfilled (40% programs unfilled). We need more Pediatric Rheumatologists!!! https://t.co/s0zPL7QhIG https://t.co/ufuuWb3rJc
Dr. John Cush RheumNow
4 years 9 months ago
NEJM Clinical Images - Tongue Necrosis in Giant Cell Arteritis. 74-yoF w/ 3-day hx of HA and tongue swelling/pain, & blindness in the right eye. Tongue was ulcerated, R temporal artery thickened. ESR 42 CRP 169 mg/L. Read rest of story... https://t.co/Npc48trzk6 https://t.co/YfikSZmjWk
Dr. John Cush RheumNow
4 years 9 months ago
Might Tofacitinib Reduce Malignancy Risk with Patients with RA?
https://t.co/lrBwN6meQR https://t.co/cW2FEGbEaH
Dr. John Cush RheumNow
4 years 9 months ago
Cochrane analysis of NSAIDs in acute #Gout - 28 trials, 3406 pts showed:
- NSAIDs > PBO 50% pain reduction @24hrs, but = to PBO for AEs & W/D
- nonselective NSAIDs = COX-2 inhib, but former has more AE & WD
- PRED - NSAIDS, but pred has more AE & WD
https://t.co/AemfID4RLN https://t.co/Ex1stFG9WG
Dr. John Cush RheumNow
4 years 9 months ago
JAK Safety -- The Lowdown on Infection: Drs. Kevin Winthrop and Jonathan Kay
https://t.co/6Um0la1yRi https://t.co/W4xHBxB2AV
Dr. John Cush RheumNow
4 years 9 months ago
Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-Related Arthritis (ERA)- Current Challenges and Future Outlook
https://t.co/O6GENGGxKm
A recent study of drugs used in type 2 diabetes (T2DM) shows that SGLT2 inhibitors have a lower risk for gout compared with those receiving DPP4 inhibitors.
Dr. John Cush RheumNow
4 years 9 months ago
Study of 408 men with inflammatory arthritis fathered 897 singleton pregnancies with 794 live births. Pregnancies conceived after the diagnosis of IA had higher rate of miscarriage (12.3 vs 7.5%, p = <0.05), even after adjusting for confounders (OR 2.03) https://t.co/Nq2lP0SXTL
Dr. John Cush RheumNow
4 years 9 months ago
BMS announced today that Orencia as 1st FDA approved drug to prevent acute graft versus host disease & may be used in bone marrow or stem cell transplantation from an unrelated donor. (Based on 186 pt RCT w/ Orencia showing better survival (98 vs 75% PBO) https://t.co/9j9fPEwKJU
